J&J Medical Connect
Neuroscience
Neuroscience

Congress Materials – Clinical Trials on Alzheimer's Disease (CTAD 2026)

 

2025 Clinical Trials on Alzheimer's Disease | Nov 16-19 | Boston, MA

This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.

Biomarker Association with Cognition: Results from the Auτonomy Phase 2 Clinical Trial

Gil Rabinovici, Reisa Sperling, Henrik Zetterberg, Xingjian Zhang, Tina Wang, Ritobrato Datta, Macarena Garcia Valdecasas Colell, Maggie Fedgchin, Tricia Thornton-Wells, Jaren Landen, Janice Wong, Gayle Wittenberg, Arthur Simen, Fiona Elwood, Gallen Triana-Baltzer, Ziad S. Saad​


This document will be available on Nov 17th 2026

CSF and Plasma Biomarker Changes After Anti-Tau Therapy: Fluid Biomarker Results from the Auτonomy Phase 2 Clinical Trial

Gallen Triana-Baltzer, Tina Wang, Reisa Sperling, Gil D. Rabinovici, Henrik Zetterberg, Shannon Leslie, Manja Schoene, Setareh Moughadam, Antonella Scaglione, Ziad S. Saad, Janice Wong, Stanley Belkowski, Gayle Wittenberg, Tricia Thornton-Wells, Maggie Fedgchin, Arthur Simen, Fiona Elwood


This document will be available on Nov 17th 2026

Impact of epitope location on Tau antibody efficacy in inhibiting Tau-seeded aggregation

Bruno Vasconcelos, Bart Hermans, Wim Van Der Elst, Matthias Bruckner, Bianca Van Broeck, Clara Theunis, Kristof Van Kolen


This document will be available on Nov 16th 2026

Performance of Plasma and CSF biomarkers for tau PET staging in Alzheimer’s Disease: evidence from mass spectrometry and immunoassays in Autonomy

Tina Wang, Shannon Leslie, Setareh Moughadam, Fatma Ayhan, Stephanie Slania, Kristof Van Kolen, Ziad S. Saad, Gallen Triana-Baltzer


This document will be available on Nov 16th 2026

Spatial Determinants of Posdinemabs Effect on Tau PET

Ziad S. Saad, Xingjian Zhang, Ritobrato Datta, Gil D. Rabinovici, Reisa Sperling, Henrik Zetterberg, Maggie Fedgchin, Tricia Thornton-Wells, Jaren Landen, Janice Wong, Gayle Wittenberg, Arthur Simen, Fiona Elwood


This document will be available on Nov 17th 2026

Utility of Clinically Scalable Biomarkers for Prescreening in Preclinical Alzheimer’s Disease: Insights from RETAIN

Federico Parisi, Adria Mallol-Ragolta, Casey R. Vanderlip, Macarena Garcia Valdecasas Colell, Stephanie Slania, Rouhollah O. Abdollahi, Gallen Triana-Baltzer, Charmaine Demanuele, Nicklas Linz, Johannes Tröger, Gayle Wittenberg, Arthur Simen, Fiona Elwood, Rachel Kolster, Ziad S. Saad, Tricia Thornton-Wells, Anahita Kyani


This document will be available on Nov 16th 2026

 

Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.

Would you like to clear and leave your conversation? Message history will be lost.